Baby products urgently pulled off shelves due to fears of choking, strangulation, death
Baby bottle self feeding devices, which were sold by Ezonedeal online nationally between May 9, 2024 and April 10, 2025, have been urgently pulled from shelves as they pose a serious risk of choking and death.
The products are available in cyan and pink, with the product codes Z3007 and Z3008.
The bottle feeding device is designed to position or prop the bottle above the baby's head while they're on their back, allowing the liquid to flow into the baby's mouth without assistance from a caregiver.
The ACCC said there was a 'risk of serious injury or death from choking, aspiration pneumonia, suffocation and ear infections'.
'There have been reports of infant fatalities associated with the use of baby bottle self-feeding devices,' the statement read.
An infant using the bottle feeding device cannot stop the flow of the bottle or pull away from the incoming liquid.
'The milk may continue to flow before the baby can swallow it,' the recall read. 'This can lead to gagging or choking, even when supervised. Choking can be silent, meaning caregivers may not notice it is happening.'
Infants can also suffer from ear infections while feeding on their back, as the milk and bacteria pools in the back of the mouth, which is connected to the ear.
'Ear infections can lead to long term damage and an increased risk of hearing or speech problems,' the recall read.
Customers with the product have been told to stop using the product immediately and dispose of it safely so it cannot be used by anyone else.
Customers can contact Ezonedeal for a full refund or store credit if it has been sold or gifted to another person
The ACCC have also urgently recalled car seat head support straps, also available for purchase on Ezonedeal online nationally between October 18 2021 and November 1 2022.
They are available in blue and red with the product codes Z1451 and Z1758.
The car seat straps, which are intended to keep a child's head secure as they ride in the back seat of the vehicle, aims to stop the child from slumping forward if they fall asleep.
However, the ACCC have pulled the items off the shelves due to fears of damaging a child's spinal cord by altering their head and spine, and cause further risk of strangulation and suffocation.
'Car seat head straps can increase the risk of spinal cord injury or death by altering head and neck alignment during a crash,' the recall read.
'They may also pose a suffocation or strangulation risk if they slip around the child's mouth or neck.'
Injuries and incidents have already occurred, the ACCC said.
There have been no reported deaths associated with the straps in Australia. However, an eight-month-old infant reportedly died in the UK due to suffocation connected to the use of a car seat head strap in August 2021.
The infant was reportedly strangled by the strap, which slipped around the child's neck after the car rolled in an accident.
Customers have been told to stop using the product immediately and dispose of it so others can't use it.
Those with the product can contact Ezonedeal for a full refund or store credit.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
11 hours ago
- ABC News
Emergency department doctor says bad flu season not to blame for record ambulance ramping in WA
A senior emergency department physician says there is no basis to the WA government's claims a worse than average flu season is contributing to record high ambulance ramping hours. Figures from St John show ambulances spent more than 7,000 hours waiting outside WA's emergency departments in July, unable to transfer patients. It amounts to an average of 225 hours a day and surpasses the previous peak in August 2022 when ramping hours were close to 6,950. The government says an ageing population is one factor for the increase and has also pointed to higher influenza cases as a contributor. But Dr Peter Allely from the Australasian College for Emergency Medicine told ABC Radio Perth the problems were structural and much deeper than a bad flu season. "It's worse than it has been, but it's not unexpected that you'll get fluctuations in the number of flu patients from year to year," Dr Allely said. Australian Medical Association WA president Dr Kyle Hoath said innovative solutions were needed. "Is there an option for the government to open and run their own aged care facility, to try and have some control over that process?," he queried. "We know that every hospital bed in the private sector, that every new medi-hotel that's being built, are not full. There are beds there that could be used as hospital beds. We need to take advantage of that." WA Health Minister Meredith Hammatt said the latest figures were disappointing but was adamant the government was doing all it could. "We are attacking this from every angle," she said. "We've delivered over 900 beds to the hospital system since 2021. We've increased staff by 30 per cent and we're looking at innovative ways that we can deliver care closer to home, where people live." Ms Hammatt said she expected a number of initiatives, already in place, would have an impact. "We're looking at all the ways that we can make a difference throughout a whole patients journey through the system, from when they first think that they may need an ambulance, right through to the point of discharge," she said. "And particularly for our older West Australians, making sure they've got appropriate care that they can access. "That's why we've done things like stood up the WA virtual emergency department, that's why we've made sure we've got a central point of coordination for ambulances through the state. "That's why we're going to deliver older adult health hubs for older West Australians and we have an election commitment to ensure that there are low interest loans available to do more aged care in WA. "And of course, we want the federal government to do more to ensure that there's aged care available for older West Australians." Opposition Leader Basil Zempilas called on Premier Roger Cook to make ambulance ramping his top priority. "They have waved the white flag," he said. "Nine years to fix it. In nine years, it's gone from 1,000 hours of ramping to a record of 7,000 hours of ambulance ramping."
ABC News
11 hours ago
- ABC News
New study finds safety protection on quad bikes is driving down farm deaths
New research has found rollover and crush protection on quad bikes is leading to a reduction in farm deaths, particularly in Victoria. A preliminary report published in the Australian and New Zealand Journal of Public Health examined whether mandatory rollover protection introduced in 2020–21 had improved safety. The lead author, honorary associate professor Tony Lower from AgHealth Australia, said the figures showed that fewer people were dying. "Of course, we'd like to see it at zero but, all being said, it is headed in the right direction, which is a really fantastic effort," Dr Lower said. The research shows that 161 people died in work-related quad bike deaths in Australia between 2001 and 2024, averaging seven fatal crashes a year. Nearly all deaths happened on farms and 65 per cent of them were the result of rollovers. The data shows that work-related quad bike deaths peaked in 2016–17, but dropped by 2024 after the new safety measures were introduced. "Rule changes like this can have significant outcomes on people's lives," Dr Lower said. "It's addressed a long-term issue with the stability of quad bikes and the potential if they do roll over to prevent crush and asphyxiation injuries." The figures revealed a significant reduction in work-related quad bike deaths and rollovers in Victoria in recent years. Deaths in Queensland also went down, but the numbers rose slightly in New South Wales. "In Victoria, there's been a larger requirement for enforcing the fitting of those operator protection devices," Dr Lower said. "They've also worked with farmers to ensure that things like helmets and the vehicles are in good maintenance. Felicity Richards, chairperson of Farmsafe Australia, said it was heartening to see a reduction "even if that is only small nationally". "We're really hopeful that quad bikes will ultimately follow that trajectory of tractors … with the introduction of rollover protection, there's been incredibly significant improvements in outcomes," Ms Richards said. Ms Richards said it would be interesting to see if further research could confirm that regulatory enforcement was making a difference. "Our focus has been on encouraging people to create a culture where they are doing things like always having (operator protection devices) on the bike, always assessing the terrain and the training of the person using it, and always wearing the helmet," she said. Dr Lower acknowledged that more research was needed into quad bike deaths since the safety changes, particularly around enforcement. "One of our recommendations is to actually look exactly at what Victoria's done, why it's worked, and look at that in more in depth," he said.
News.com.au
12 hours ago
- News.com.au
Scott Power: ASX health stocks stumble but rotation into sector ‘picks up steam'
ASX heath sector falls 0.65 % in past five days but returns 9% in July in a strong comeback 'Mostly pretty good' June quarterly reporting season comes to end Clarity Pharmaceuticals completes $203 million capital raise to institutional investors Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. After 5% and 5.4% gains over the past two weeks and being up for most of the week the ASX Health Care Index (ASX:XHJ) fell 0.65% in the past five days after heavy falls across broader markets on Friday as US tariff concerns again played on investor sentiment. The benchmark S&P/ASX 200 (ASX:XJO) finished the week fairly flat, up 0.01%. However, in some good news the healthcare sector has had a strong start to FY26 up 9% in July after a disappointing FY25 in which it finished down 4%. "The rotation into healthcare seems to be picking up steam and our sense is that this is likely to continue into FY26," Morgans' senior healthcare analyst Scott Power said. "The small end of the sector is looking particularly attractive." ImpediMed doubles unit sales as Mach7 welcomes new CEO As the June quarter reporting season wraps up, Power described it as 'mostly pretty good' for the sector with a few noteworthy ones released this week. ImpediMed (ASX:IPD) sold a record 44 of its lymphodema detection devices called Sozo in its target US market during the June quarter, double the March quarter. Total contract value was also a record with $6.3 million for the quarter. "It was a solid quarter and I think they've really started to turn the corner in terms of the US install base," Power said. Morgans maintains a speculative buy on ImpediMed with a 12-month 15 cent target price. Health imaging stock Mach7 Technologies (ASX:M7T) reported its Q4 FY25 result with Power saying while there were no major surprises and most information flagged in a recent trading update, outlook from its new CEO Terri Thomas was positive. Mach7 reiterated FY25 guidance of revenue between $33m-$34m and CARR of ~$30m-$31m. Power this week caught up with Thomas, who took over on July 1 and was previously head of former ASX-listed breast imaging company Volpara Technologies, which was taken over by South Korean firm Lunit last year. "In the first 30 days Terri has been there she's made some changes and with her guiding hand I think in the next 12 months we're going to see Mach7 kick some big goals," Power said. "The company is moving towards profitability as well." Morgans has an add rating on Mach7 and 12-month target price of $1.37. Provider of oral appliance treatments for sleep-related breathing disorders and obstructive sleep apnea (OSA) Somnomed (ASX:SOM) delivered top-line growth ahead of expectations, with strong performances in key markets North America and Europe. Growth was driven by both new and returning customers, as well as successful price increases across its product range. With previous manufacturing delays now largely resolved, SomnoMed is planning to expand production capacity by more than 25% in FY26. In a note to client analyst Iain Wilkie said the increased manufacturing capacity combined with more efficient turnaround should leave Somnomed in a strong place to handle expected continued growth over the short-term. "FY25 has been a strong year for SOM and the market has responded positively to it, up ~50% over the past 12 months and up 250% since May 2024 following the overhaul of the business with a new management team, repayment of its debt facilities, and addressing manufacturing inefficiencies," Wilkie wrote. Consensus target price for Somnomed is 80 cents. Micro-X supply agreement marks turning point Micro-X (ASX:MX1) rose ~40% on Wednesday after news it had tapped into a network of 700 hospitals with a three-year supply agreement through a major US healthcare provider, the first of its kind for the company. Micro-X secured the contract after a highly competitive tender process and a successful in-hospital trail of its Rover Plus mobile radiology system. The company is in discussions with a second major procurement group for a similar supply agreement. It's good news for the company, which has undertaken a strategic review of its operations and is now focusing on medical imaging for its cold cathode X-ray technology, halting further work on its Argus bomb detection device after the commercial launch didn't attract sufficient customer interest. "The agreement they've signed is good validation that their strategy on focusing on the medical imaging side of the business is paying off," Power said. Micro-X is also developing a head CT scanner and full body lightweight portable CT scanner. A security project – an airport baggage scanner self-check-in – is being funded by the US Department of Homeland Security. "They are getting paid to develop that system but the core focus is back on medical imaging," Power said. "Clearly it is now paying off and they're talking about potential other agreements coming through. Morgans has a speculative buy rating on Micro-X and 12-month target price of 17 cents. Clarity completes mammoth $203 milllion capital raise Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) completed a large $203m institutional placement, struck at a 15% premium to the company's 15-day average price, to fund their clinical program. "The capital raise was a pretty big achievement for them," Power said. Executive chairman Dr Alan Taylor told Stockhead the 'fast, well executed and sizeable' placement was to a small group of local institutional investors "close to the company'. "I have never done a deal that fast," Taylor said. "A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group ." Power's Powerplay: 'Solid set of numbers' for Aroa New Zealand soft tissue repair company Aroa Biosurgery (ASX:ARX) reported its third consecutive quarter of positive net cash flow since listing on the ASX in July 2020 and reaffirmed its FY26 revenue guidance. Operating on the New Zealand financial year, cash flow from operations for the June quarter was NZ$1.7m, with cash receipts of $22.5m. Net cash outflows from investing activities for the quarter were NZ$900,000, primarily reflecting routine capital expenditure. Net cash flow was NZ$500,000 with total cash on hand increasing by NZ$200,000, after adjusting for the impact of movements in exchange rates. The company ended the quarter with a cash balance of NZ$22.2m. "Importantly, the company reaffirmed full-year FY26 total revenue guidance of NZ$92–100m representing growth of 20% at the top end which is where we sit and are happy to sit there," Power said. "They've reported a solid set of numbers." Normalised EBITDA for FY26 of NZ$5–8m represents growth of 19–90% on FY25. "Aroa has really turned the corner and is now producing sustainable profits going forward," Power said. Morgans maintains a speculative buy and 12-month target price of 77 cents on Aroa. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While Aroa Bisurgery is a Stockhead advertiser, the company did not sponsor this article.
